Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Income from Continuing Operations (2016 - 2025)

ProQR Therapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 10589303.85 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 1.7% to 10589303.85 in Q4 2025 year-over-year; TTM through Dec 2025 was 49023477.82, a 48.58% decrease, with the full-year FY2025 number at 49104011.62, down 65.51% from a year prior.
  • Income from Continuing Operations hit 10589303.85 in Q4 2025 for ProQR Therapeutics, up from 13191617.65 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PRQR hit a ceiling of 3876795.27 in Q2 2024 and a floor of 19987022.04 in Q3 2022.
  • Historically, Income from Continuing Operations has averaged 12634493.69 across 5 years, with a median of 12044732.13 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: surged 59.75% in 2023 and later plummeted 257.65% in 2025.
  • Tracing PRQR's Income from Continuing Operations over 5 years: stood at 19822728.64 in 2021, then soared by 35.87% to 12712282.17 in 2022, then surged by 46.95% to 6743991.35 in 2023, then plummeted by 59.73% to 10772510.23 in 2024, then grew by 1.7% to 10589303.85 in 2025.
  • Business Quant data shows Income from Continuing Operations for PRQR at 10589303.85 in Q4 2025, 13191617.65 in Q3 2025, and 13865374.22 in Q2 2025.